BIOARCTIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 216 SEK | +1.12% |
|
-4.68% | -19.34% |
| 06-10 | Global markets live: ABB, Roche, Microsoft, Apple, Tesla... |  |
| 06-10 | BioArctic Reports US FDA's Acceptance of Biologics License Application for Leqembi IV Maintenance Dosing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,357 | 8,401 | 10,497 | 23,972 | 23,651 | 19,078 | - | - |
| Enterprise Value (EV) 1 | 7,271 | 7,422 | 9,664 | 23,176 | 23,044 | 18,183 | 17,869 | 17,149 |
| P/E ratio | 94.9 x | -122 x | -87.6 x | -2,092 x | 103 x | 9,118 x | 44.1 x | 17.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 29.7 x | 127 x | 454 x | 104 x | 38.4 x | 37.2 x | 18.3 x | 9.81 x |
| EV / Revenue | 25.8 x | 113 x | 418 x | 101 x | 37.4 x | 35.5 x | 17.1 x | 8.82 x |
| EV / EBITDA | 59.7 x | -100 x | -76.3 x | -8,251 x | 85 x | -45,457 x | 38.4 x | 19.3 x |
| EV / FCF | 22.5 x | -70.8 x | -66.7 x | -522 x | - | 87.6 x | 39.9 x | 19.4 x |
| FCF Yield | 4.45% | -1.41% | -1.5% | -0.19% | - | 1.14% | 2.51% | 5.15% |
| Price to Book | 8.57 x | 9.26 x | 13.3 x | 30.5 x | 22.6 x | 18.5 x | 13 x | 12.1 x |
| Nbr of stocks (in thousands) | 88,060 | 88,060 | 88,060 | 88,132 | 88,315 | 88,323 | - | - |
| Reference price 2 | 94.90 | 95.40 | 119.2 | 272.0 | 267.8 | 216.0 | 216.0 | 216.0 |
| Announcement Date | 20-02-06 | 21-02-04 | 22-02-03 | 23-02-03 | 24-02-14 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 281.8 | 65.94 | 23.15 | 229.9 | 616 | 512.2 | 1,044 | 1,945 |
| EBITDA 1 | 121.7 | -74 | -126.6 | -2.809 | 271.1 | -0.4 | 464.8 | 887 |
| EBIT 1 | 112.5 | -85.01 | -139.7 | -17.44 | 252.6 | 3.771 | 438.3 | 1,230 |
| Operating Margin | 39.92% | -128.92% | -603.66% | -7.59% | 41.01% | 0.74% | 42% | 63.26% |
| Earnings before Tax (EBT) 1 | 113 | -86.69 | -140.5 | -11.17 | 276.5 | 19.13 | 542.4 | 1,394 |
| Net income 1 | 88.5 | -68.52 | -119.8 | -11.18 | 229.2 | 2.855 | 433 | 1,102 |
| Net margin | 31.41% | -103.9% | -517.54% | -4.86% | 37.22% | 0.56% | 41.48% | 56.63% |
| EPS 2 | 1.000 | -0.7800 | -1.360 | -0.1300 | 2.590 | 0.0237 | 4.899 | 12.49 |
| Free Cash Flow 1 | 323.9 | -104.9 | -144.8 | -44.4 | - | 207.5 | 448 | 883.7 |
| FCF margin | 114.94% | -159.02% | -625.78% | -19.32% | - | 40.51% | 42.92% | 45.43% |
| FCF Conversion (EBITDA) | 266.06% | - | - | - | - | - | 96.38% | 99.62% |
| FCF Conversion (Net income) | 365.98% | - | - | - | - | 7,268.21% | 103.48% | 80.22% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-06 | 21-02-04 | 22-02-03 | 23-02-03 | 24-02-14 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 2.746 | 208.8 | 11.02 | 29.64 | 49.64 | 356.6 | 108.5 | 146.6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | -100.9 | 131 | -78.09 | -73.1 | -79.91 | 218.1 | -50.65 | 13.76 |
| Operating Margin | - | - | -3,673.31% | 62.73% | -708.35% | -246.63% | -160.98% | 61.16% | -46.69% | 9.39% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | -44.26 | 293.9 | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5000 | 3.310 | -1.160 | 1.410 | -0.9900 | -0.6500 | -0.9000 | 2.400 | -0.6000 | 0.3000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-04-28 | 23-04-27 | 23-07-12 | 23-11-08 | 24-02-14 | 24-05-17 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,086 | 979 | 833 | 795 | 607 | 895 | 1,209 | 1,929 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 324 | -105 | -145 | -44.4 | - | 208 | 448 | 884 |
| ROE (net income / shareholders' equity) | 8.9% | -7.28% | -14.1% | -7.1% | 25% | 4.03% | 28% | 43% |
| ROA (Net income/ Total Assets) | 6.87% | -6.14% | -12.3% | -1.27% | 22.4% | -5.24% | 35% | 36.8% |
| Assets 1 | 1,289 | 1,117 | 974 | 878.9 | 1,022 | -54.45 | 1,238 | 2,995 |
| Book Value Per Share 2 | 11.10 | 10.30 | 8.960 | 8.920 | 11.90 | 11.70 | 16.60 | 17.90 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 12.8 | - | 21 | 16.8 | 30.5 |
| Capex / Sales | - | - | - | 5.55% | - | 4.1% | 1.6% | 1.57% |
| Announcement Date | 20-02-06 | 21-02-04 | 22-02-03 | 23-02-03 | 24-02-14 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
216
SEK
Average target price
368
SEK
Spread / Average Target
+70.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.34% | 1.81B | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +34.92% | 38.48B | |
| +12.62% | 26.36B | |
| -12.11% | 26.22B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- BIOA B Stock
- Financials BioArctic AB
